title: Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
authors.affiliation: Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27705, USA. oconn002@mc.duke.edu
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Gattis
authors.forename: Kirkwood F
authors.initials: KF
authors.lastname: Adams
authors.forename: Monica R
authors.initials: MR
authors.lastname: Shah
authors.forename: Aline
authors.initials: A
authors.lastname: Frey
authors.forename: Mihai
authors.initials: M
authors.lastname: Gheorghiade
mesh_terms: D004311:Double-Blind Method; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use*; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000502:physiology; D012008:Recurrence; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D011725:Pyridines; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D013777:Tetrazoles; D014665:Vasodilator Agents; C120582:tezosentan